

A story about signals......



.....diseases often don't give (early) signals that you can feel or see

and people often miss disease signals



Late-stage disease detection leads to loss of life and increased costs

50% of cancers and CVD's are detected at advanced stage!





2 With early detection:

Survival rates:	UP	\rightarrow	Stage 1 cancer: 60 - 98 %	VS	Stage 4 cancer: 6 - 23 %
Healthcare costs:	DOWN	\rightarrow	@ €7.000 − €83.000	VS	@ € 105.000 – 390.000



The solution is a personalized Multi Disease Early Warning System (MDEWS)



Easy and noninvasive sample collection @ home




Personalized analysis in stead of population average



Cost effective → multiple organs @ once




9 disease panels @ av. sensitivity of 85%



We use microRNAs as biomarker for disease onset

- 1 Balancekeepers: turned on in case of organ disruption.
- Only **2.000 microRNA's** so algorithms are explainable.
- 3 One measurement, low cost, multi disease detection.

	Complexity	More than cancer	Cost-effective
MicroRNA	Low	Yes	Yes
Tumor DNA	High	No	No





Via the URIMON study we acquire early and personalized disease samples

The Urimon study: Unique samples that capture the early stages of disease

• Since 2019: > **5.000** participants, > **200.000** samples

- Healthy at start
- Age 45+, M/F
- Urine, Blood, Health data







242 cancer and 264 CVD cases, and growing...

A preliminary business model will secure timely revenue

Revenue Model

Baseline development



@ Start

2 urine tests per year




Subscription model

Standard of care Follow up



Included in subscription



Earlyvangelists among Urimon participants and existing partnerships












We are lowering costs for broad application & reimbursement






Through automation costs of microRNA profiling **can be brought down to ~€25** to become eligible for <u>reimbursement and population screening</u>



USPs: Sensitivity @ early detection, ease of use & multiple diseases in one test





Regulatory strategy in place & competitive advantage on multiple subjects

Regulatory strategy in place & structured dialogue Health data provider → diagnostics provider



Gert de Vries



Charlotte Hess bsi.

Competitive advantage:

- 1. Unique sample- & data collection
- 2. Use of MicroRNA profiles for disease detection
- 3. MicroRNA preservation, isolation & NGS profiling
- 4. MicroRNA panels & algorithms



Barend Bouma





The URIMON team has all the expertise to reach her goals




Bram de Moor LLM MBI Business Model & Go 2 Market


- 12 yrs+ business development in LSH: 3 start-ups
- Legal and international marketing & sales expert in FMCG
- Multiple marketing prizes



Johan de Rooij PhD MBI R&D & RaQa compliance

- 20 yrs+ cancer biologist
- Biomarker science
- Research leader & multiple start ups
- RaQa experience





Founder Osasense





Maaike Dekker MSc Molecular biology

- **Next Gen Sequencing (NGS)**
- Urine & blood chemistry
- Bio informatics



Utrecht

UNIVERSITY MST

Modeling & machine learning

- statistics
- HTA, data visualisation
- prediction models



HAN_UNIVERSITY
OF APPLIED SCIENCE

Diemer Harbers BSc Laboratory and quality

- Body fluid processing
- **Quality management**
- Analytical chemistry
- Bio informatics



Dr. Julia Hermann Ethics of early disease detection University of Twente

UNIVERSITY OF TWENTE.



Dr. Hinne Rakhorst MD Health data and registries surgeon oncology, MST Hospital









Dr. Michiel Pegtel Biomarker science Amsterdam UMC










Jannie van den Broek Go-to-market-strategy North Star Advice









- 20 years+ mathematical
- Machine learning & Universiteit


The ask & milestones to reach the market

Raising € 3,5 M to reach next value inflection in 2026 (validation)

Expand study & Biobank

€ 1 M committed by current investors.

Raising subsequent € 3,5 M to enter the market in 2027






Reimbursement

2031

Using urine for disease detection is already very old......





.....and we are bringing it to the 21st century!

Will you join us on our mission?



▲ Johan de Rooij (L) en Bram de Moor (R) willen naar 10.000 deelnemers aan het onderzoek. "Mensen die nu al betrokken zijn, willen iets voor de maatschappij doen", ontdekten ze. © Robin Hilberink

SUMMARY:

- 1. Urine test for the early detection of disease.
- 2. MicroRNAs as biomarkers.
- 3. Unique study & biobank with early stage samples as resource for validation.
- 4. Raising € 3,5 M of which € 1 M secured.

Bram de Moor +31.629.09.23.93 www.urimon.nl bdemoor@urimon.nl

